Impact de la réforme de l’assurance maladie en Tunisie sur l’offre et la demande des médicaments
This thesis proposes to determine the effect of the Health insurance reform in Tunisia on pharmaceutical demand and supply. For this purpose, we present the main characteristics of the Tunisian pharmaceutical market, with describing the objectives and modalities of implementation of Health insurance reform (Chapter 1). Then we demonstrate empirically the importance of generic competition (Chapter 2). Finally, we determine the impact of the Health insurance reform, specifically the introduction of reference price system on prices and market shares of four selected molecules (Chapter 3). It has information on prices and quantities of four selected molecules (eleven different presentations) from the third quarter 2002 to the fourth quarter 2008. In the first chapter, we specify the Tunisian Health care system, with explaining the characteristics of the pharmaceutical market. Then, we describe the Health insurance system, the reform objectives, particularly, on pharmaceuticals. And we define the reference price system and the modalities for its implementation. In the second chapter, we study the effect of the generic competition on prices and market shares. We find that the presence of generic products on the pharmaceutical market, offers the possibility to switch for the cheaper one. In addition, we find that the brand name price’s drop intensely than the average price of generic. Moreover, it seems that the decrease of the generic-to-brand price ratio entails an increase (decrease) in market share of generics (brand name’s drug). This increase in market share of generics is attributed to price changes. In addition, the empirical results suggest that the generic share depends on, and is influenced by, generic price. In addition, we find the number of generic entrants to be a key determinant of the level of generics’ share and generic-to-brand price ratio. In the third chapter, we examine the effect of the introduction of Reference pricing (RP) on price. It shows that the brand name’s price decline after the imposition of reform and the introduction of reference pricing, and generic competition plays an important role in this process. We find that the reference price system has a strong effect of reducing prices of pharmaceuticals under this regime; the effect is stronger for brand name than generic versions. This confirms that the RP encourages competition. The reference pricing system induces a change in the market for medicines to generic versions.
|This book is provided by Paris Dauphine University in its series Economics Thesis from University Paris Dauphine with number 123456789/7671 and published in 2009.|
|Contact details of provider:|| Web page: http://www.dauphine.fr/en/welcome.html|
More information through EDIRC
References listed on IDEAS
Please report citation or reference errors to , or , if you are the registered author of the cited work, log in to your RePEc Author Service profile, click on "citations" and make appropriate adjustments.:
- Stephen Bond & Anke Hoeffler & Jonathan Temple, 2001.
"GMM Estimation of Empirical Growth Models,"
2001-W21, Economics Group, Nuffield College, University of Oxford.
- Bond, Stephen Roy & Hoeffler, Anke & Temple, Jonathan, 2001. "GMM Estimation of Empirical Growth Models," CEPR Discussion Papers 3048, C.E.P.R. Discussion Papers.
- Ashenfelter, Orley C, 1978. "Estimating the Effect of Training Programs on Earnings," The Review of Economics and Statistics, MIT Press, vol. 60(1), pages 47-57, February.
- Mats A. Bergman & Niklas Rudholm, 2003. "The Relative Importance of Actual and Potential Competition: Empirical Evidence From the Pharmaceuticals Market," Journal of Industrial Economics, Wiley Blackwell, vol. 51(4), pages 455-467, December.
- Brekke, Kurt R. & Grasdal, Astrid L. & Holms, Tor Helge, 2009. "Regulation and pricing of pharmaceuticals: Reference pricing or price cap regulation?," European Economic Review, Elsevier, vol. 53(2), pages 170-185, February.
- Brekke, Kurt R. & Grasdal, Astrid L. & Holmås, Tor Helge, 2006. "Regulation and Pricing of Pharmaceuticals: Reference Pricing or Price Cap Regulation?," Working Papers in Economics 14/06, University of Bergen, Department of Economics.
- Kurt R. Brekke & Astrid L. Grasdal & Tor Helge Holmås, 2007. "Regulation and Pricing of Pharmaceuticals: Reference Pricing or Price Cap Regulation?," CESifo Working Paper Series 2059, CESifo Group Munich.
- Thomas Aronsson & Mats Bergman & Niklas Rudholm, 2001. "The Impact of Generic Drug Competition on Brand Name Market Shares – Evidence from Micro Data," Review of Industrial Organization, Springer;The Industrial Organization Society, vol. 19(4), pages 423-433, December.
- Stephen Bond & Anke Hoeffler, 2001. "GMM Estimation of Empirical Growth Models," Economics Series Working Papers 2001-W21, University of Oxford, Department of Economics. Full references (including those not matched with items on IDEAS)
When requesting a correction, please mention this item's handle: RePEc:dau:thesis:123456789/7671. See general information about how to correct material in RePEc.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: (Alexandre Faure)
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
If references are entirely missing, you can add them using this form.
If the full references list an item that is present in RePEc, but the system did not link to it, you can help with this form.
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your profile, as there may be some citations waiting for confirmation.
Please note that corrections may take a couple of weeks to filter through the various RePEc services.